Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.67B | $5.72B | $2.82 |
| 2024 | $31.38B | $2.58B | $1.26 |
| 2023 | $30.33B | $4.93B | $2.44 |
| 2022 | $29.32B | $14.96B | $7.44 |
| 2021 | $24.70B | $4.38B | $2.74 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $1.37 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$1.36 vs $1.27beat
- Wed, Apr 29$1.24 vs $1.16beat
- Wed, Feb 4$0.68 vs $0.64beat
- Wed, Oct 29$1.48 vs $1.26beat
- Wed, Jul 30$1.23 vs $1.12beat
- Wed, Apr 30$1.13 vs $1.08beat
Estimates and results for GSK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GSK's reported EPS growth of 0.7% a year over 4 years.
- EPS in 5 years
- $2.92
- Implied price
- $37.99
- Return from $49.52
- -5.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.89 — -61.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -9.3% | -20.6% | -17.4% | -14.6% | -12.1% | -9.9% |
| -4.3% | -16.3% | -12.8% | -9.9% | -7.3% | -4.9% |
| 0.7% | -11.9% | -8.3% | -5.2% | -2.4% | 0.1% |
| 5.7% | -7.5% | -3.7% | -0.5% | 2.4% | 5.0% |
| 10.7% | -3.1% | 0.8% | 4.3% | 7.3% | 10.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newscnbc.com·4d ago·Positive
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
View source ↗